31 August 2021

Combioxin SA, a clinical-stage biotechnology company based in Epalinges, Switzerland, entered into a worldwide licensing agreement with Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX), a fully integrated pharmaceutical company based in Woodcliff Lake, NY, USA, for the commercial rights to CAL02, a novel first-in-class antitoxin agent ready for Phase 2b/3 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs.

Under the Agreement, Eagle Pharmaceuticals, Inc. will be solely responsible for further clinical development of CAL02 and will make an upfront payment, followed by additional payments upon achievement of development milestones, regulatory approval and based upon commercial sales. Eagle expects to invest USD 35 million to achieve interim results. These interim results are expected in the first half of 2023.

CAL02 is designed to be an add-on therapy to antibiotics to neutralize virulence effectors. CAL02 consists of liposomes that capture and neutralize bacterial toxins produced by a broad range of Gram-positive and Gram-negative bacteria. Bacterial toxins play a critical role in severe, complicated, and resistant infections. They are known to dysregulate inflammation, cause organ damage and impede immune defense. Unlike traditional antibacterial drugs, CAL02 does not target bacteria directly.

VISCHER advised Combioxin SA on all legal issues related to the license agreement. The VISCHER team was led by Christian Wyss (Partner, Corporate/M&A) with Pauline Pfirter (Associate, Corporate/M&A) and Luzius Zumstein (Senior Associate, Corporate/M&A)

Press release

Categories: Corporate and Commercial, Intellectual Property, Life Sciences, Pharma, Biotech, Startup Desk

You are currently offline. Some pages or content may fail to load.